Bausch & Lomb Incorporated.

Feb 25, 2019

Bausch + Lomb Announces FDA Approval Of LOTEMAX® SM (loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery

Sep 05, 2018

Bausch + Lomb Announces Publication Of Pivotal Phase 3 Data On Loteprednol Etabonate Ophthalmic Gel, 0.38% In Journal Of Cataract And Refractive Surgery

May 02, 2018

Bausch + Lomb ULTRA® Contact Lenses Receive FDA Approval for Extended Wear Indication

Apr 27, 2018

Bausch + Lomb Will Present Scientific And Clinical Research During The Association For Research In Vision And Ophthalmology Meeting

Apr 19, 2018

Bausch + Lomb Reports More Than Two Million Used Contact Lens Materials Recycled Through ONE by ONE Program

Apr 11, 2018

Bausch + Lomb to Showcase New Scientific Data During the Annual Meeting of the American Society of Cataract and Refractive Surgery

Dec 22, 2017

Bausch + Lomb Receives FDA Approval of LUMIFY(TM) - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness

Oct 03, 2017

Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe